Valion Bio's Velocity Bioworks Secures Exclusive Commercial License to LarmorBio's BioScan-NMR™ Platform

First Commercial Installation Targeted for July 2026 in San Antonio; Strategic Reference Site Positions Velocity Bioworks at the Forefront of Next-Generation NMR-Based Diagnostics > see full press release https://valionbio.com/valion-bios-velocity-bioworks-secures-exclusive-commercial-license-to-larmorbios-bioscan-nmr-platform/

Next
Next

LarmorBio to present clinical data with Quest Diagnostics at the World Congress on Insulin Resistance